DURECT Launches Phase Ib NASH Clinical Trial

Streetwise Reports notes DURECT Corp. (DRRX: NASDAQ) is enrolling patients in its Phase Ib non-alcoholic steatohepatitis (NASH) trial. A multicenter, open-label study will evaluate the company’s lead drug, DUR-928, in patients with NASH. A total of 60 patients will be enrolled, 20 per dose.